Published: March 2014 | Pages: 53 | Format: PDF and Online
The present Competitive Intelligence Report about EGF-R Antibodies –Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted combined 2013 sales of US$ 2,486 mln. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies.
The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Table of Contents
1. EGF-R Antibodies –Biosimilars and Biosuperiors
Marketed EGF-R Antibodies
- Erbitux Sales & Pipeline
- Vectibix Sales & Pipeline
- Nimotuzumab Pipeline
EGF-R Antibody Biobetters/Biosuperiors
- Engineered EGF-R Antibodies
- Bi- and Multispecific EGF-R Antibodies
- EGF-R Antibody-Drug Conjugates
EGF-R Antibody Biosimilars
- Cetuximab Biosimilars
- Panitumumab Biosimilars
2. Corporate EGF-R Antibody Biosimilar & Biobetter Pipelines